Skip to content

Brimonidine in Rosacea

Efficacy and Safety of Combining Doxycycline With Pulsed Dye Laser Versus Topical Brimonidine 0.33% in the Treatment of Erythematotelangiectatic Rosacea: a Comparative Clinical and Dermoscopic Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05401422
Enrollment
45
Registered
2022-06-02
Start date
2022-05-25
Completion date
2022-09-15
Last updated
2022-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Brief summary

Rosacea is a chronic and relapsing inflammatory cutaneous disorder with highly variable prevalence worldwide.

Detailed description

In our study, we will compare the safety, efficacy, and adverse effects of low-dose oral doxycycline alone versus combined with pulsed dye laser or topical brimonidine in treating erythematotelangiectatic rosacea in an attempt to build a treatment strategy in a disease with complex pathogenesis.

Interventions

OTHERtreatment

types

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patient with current erythematotelangiectatic rosacea

Exclusion criteria

\- Pregnant females. 2-Patients on systemic steroids. 3-Patients complaining of other dermatological disorders mainly photosensitive cutaneous disorder. 4- Patients receiving any systemic treatment including retinoids for the previous 1 month or any topical treatment for the previous 2 weeks or any laser sessions for the previous 3months for erythematotelangiectatic rosacea at least.

Design outcomes

Primary

MeasureTime frameDescription
Clinical erythema assessment scale3 monthsclinical scale

Secondary

MeasureTime frameDescription
Thickness of capillaries by dermoscope3 monthsAssessment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026